|
The
agency said it does not plan to hold a meeting of the outside
experts on Pfizer's request, concluding the request does not
raise questions that would benefit from additional discussion by
the members of the committee.
The decision from the FDA will likely come before a U.S. Centers
for Disease Control and Prevention (CDC) advisory panel meets on
Friday to discuss expanding the eligibility for booster doses of
Pfizer/BioNTech's vaccine, currently allowed for select groups
of people.
Earlier this month, Pfizer had requested the FDA to authorize
booster doses of the vaccine in all adults, presenting recent
data showing the shot would help prevent disease across ages.
The company's third dose has been authorized for
immunocompromised individuals, people aged 65 and above, all
those at high risk of severe disease, and people who are
regularly exposed to the virus.
U.S. President Joe Biden's administration in August announced
plans to roll out booster doses for all adults in September.
The CDC sets U.S. adult and childhood immunization schedules
based on recommendations from the Advisory Committee on
Immunization Practices.
(Reporting by Mrinalika Roy in Bengaluru, Ahmed Aboulenein in
Washington and Michael Erman in New York; Editing by Vinay
Dwivedi)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|
